drugset
drugset / Trial / NCT04667793

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

NCT04667793 ↗

Phase 2 Unknown 15 enrolled Shanghai Pulmonary Hospital, Shanghai, China
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, single-arm, open-label study to evaluate the efficacy and safety of neoadjuvant Toripalimab + chemotherapy followed by radical surgery as first-line treatment in patients with locally advanced thymic epithelial tumor.

Timeline

Start
2021-01-31
Primary completion
2023-09-30
Completion
2024-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amycin Unknown 50 mg/m2 Intravenous
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Cisplatin Other / unclassified 50 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Toripalimab Monoclonal antibody 200 mg Intravenous

Indications

thymic epithelial neoplasm